Wire · opportunities
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
The FDA has scheduled a Type A meeting with Ascelia Pharma on September 9, 2026, to discuss the New Drug Application for Orviglance.
This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
You must prepare for FDA feedback that could redefine your clinical or regulatory strategy for drug approval timelines. This meeting opens a critical window to accelerate your path to market or uncover key obstacles ahead.
◆ Related on Wire
◆ Topics